Background: Normal levels of plasma antithrombin (AT) activity might decrease heparin requirements to achieve an adequate level of anticoagulation during treatment with extracorporeal membrane oxygenation (ECMO). Acquired AT deficiency during ECMO is common, but formal recommendations on target, timing, and rate of AT supplementation are lacking. Thus, we conceived a pilot trial to evaluate the feasibility and safety of prolonged AT supplementation in patients requiring veno-venous ECMO for respiratory failure.
Methods: Grifols Antithrombin Research Awards (GATRA) is a prospective, randomized, single blinded, multicenter, controlled two-arm trial. Patients undergoing veno-venous ECMO will be randomized to either receive AT supplementation to maintain a functional AT level between 80 and 120% (AT supplementation group) or not (control group) for the entire ECMO course. In both study groups, anticoagulation will be provided with unfractionated heparin following a standardized protocol. The primary endpoint will be the dose of heparin required to maintain the ratio of activated partial thromboplastin time between 1.5 and 2. Secondary endpoints will be the adequacy of anticoagulation and the incidence of hemorrhagic and thrombotic complications.
Discussion: GATRA is a pilot trial that will test the efficacy of a protocol of AT supplementation in decreasing the heparin dose and improving anticoagulation adequacy during ECMO. If positive, it might provide the basis for a future larger trial aimed at verifying the impact of AT supplementation on a composite outcome endpoint including hemorrhagic events, transfusion requirements, and mortality.
Trial Registration: ClinicalTrials.gov, NCT03208270 . Registered on 5 July 2017.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558738 | PMC |
| http://dx.doi.org/10.1186/s13063-019-3386-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
pneumonia followed by lower gastrointestinal ischemic necrosis: a case report.
Front Med (Lausanne)
January 2025
Medical Center of Trauma and War Injury, Daping Hospital, Army Medical University, State Key Laboratory of Trauma and Chemical Poisoning, Research Institute of Surgery, Chongqing, China.
Background: Psittacosis, also known as parrot fever, is an uncommon infectious disease caused by (C. psittaci). While infections are usually not life-threatening, the pathogenesis and associated complications are not yet fully understood.
View Article and Find Full Text PDFExtracorporeal membrane oxygenation for adults with respiratory failure secondary to cardiorespiratory disease: evolving indications and clinical practice.
Breathe (Sheff)
January 2025
Critical Care Unit, Royal Brompton Hospital, London, UK.
Extracorporeal membrane oxygenation (ECMO) can support patients with severe cardiorespiratory failure presenting with hypoxia who would otherwise have not survived. Patient selection for ECMO is challenging and relies on the integration of physiological variables with an assessment of reversibility of the underlying condition or suitability for transplantation. In this review, we focus on patients with cardiorespiratory disease who may present with severe hypoxia.
View Article and Find Full Text PDFAwake Venovenous Extracorporeal Membrane Oxygenation in the Intensive Care Unit: Challenges and Emerging Concepts.
J Cardiothorac Vasc Anesth
January 2025
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address:
Extracorporeal membrane oxygenation (ECMO) is an advanced treatment for severe respiratory failure. Implantation of ECMO before invasive ventilation or extubation during ECMO has been reported and is becoming increasingly popular. Avoidance of sedation and invasive ventilation during ECMO (commonly referred to as "awake ECMO") may have potential advantages, including a lower rate of delirium, shorter mechanical ventilation time, and the possibility of undergoing early rehabilitation and/or physiotherapy.
View Article and Find Full Text PDFVeno-venous ECMO intervention for respiratory failure after trauma from a motor vehicle collision.
BMJ Case Rep
January 2025
Department of General Surgery, Royal Brisbane and Women's Hospital, Queensland Health, Brisbane, Queensland, Australia.
Extracorporeal membrane oxygenation (ECMO) has emerged as a salvage therapy in refractory respiratory failure. Within the literature, there is evidence to support the use of ECMO in severe thoracic trauma; however, there is minimal information on its applicability in mild to moderate thoracic trauma. This report describes a man in his 50s who suffered thoracic trauma following a motor vehicle accident, who, despite maximal medical therapy, experienced deterioration in respiratory function, requiring the commencement of veno-venous ECMO on day 5 post injury and subsequently achieved excellent functional recovery.
View Article and Find Full Text PDFPerioperative extra corporeal membrane oxygenation in neonates with transposition of the great arteries: 15 years of experience.
Eur J Cardiothorac Surg
January 2025
Division of Pediatric Intensive Care, Department of Intensive Care, Leiden University Medical Centre, Leiden, Netherlands.
Background: Extracorporeal membrane oxygenation (ECMO) can act as a bridge to recovery in both pre-and postoperative patients with transposition of the great arteries (TGA). However, literature on its use in these patients is scarce.
Methods: Retrospective single-centre cohort study encompassing all TGA patients who received ECMO between January 2009 and March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!